Clinical Trial Info

Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Moderate and Severe COVID-19 (AVICOVID-2)

Authored by
Staff

The primary outcome of this Phase 2/3 study will be progression in severity of COVID-19 (i.e. moderate progressing to severe or critical OR severe progressing to critical) over 28 days. Secondary outcomes will include blood oxygenation as measured by pulse oximetry, dyspnea, exercise tolerance, and levels of TNFα IL-6 and other cytokines.